Recombinant Human VSIG2 Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 9815-VS

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
9815-VS-100
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

NS0

Accession #

Q96IQ7-1

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all VSIG2 Proteins and Enzymes »

Product Specifications

Source

Mouse myeloma cell line, NS0-derived human VSIG2 protein
Human VSIG2
(Val24-Ala243)
Accession # Q96IQ7-1		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Val24

Predicted Molecular Mass

50 kDa

SDS-PAGE

54-65 kDa, reducing conditions

Activity

Measured by its ability to inhibit anti-CD3 antibody induced IFN-gamma secretion by human peripheral blood mononuclear cells (PBMC).
The ED50 for this effect is 5-25 μg/mL.

Scientific Data Images for Recombinant Human VSIG2 Fc Chimera Protein, CF

Recombinant Human VSIG2 Fc Chimera Protein SDS-PAGE

Recombinant Human VSIG2 Fc Chimera Protein SDS-PAGE

2 μg/lane of Recombinant Human VSIG2 was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® blue staining, showing bands at 54-65 kDa and 100-130 kDa, respectively.

Formulation, Preparation and Storage

9815-VS
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution
Reconstitute at 500 μg/mL in PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
  • 12 months from date of receipt, ≤ -20 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.

Background: VSIG2

V-set and immunoglobulin domain-containing protein 2 (VSIG2), also known as cortical thymocyte-like protein (CT-like protein), is a member of the immunoglobulin superfamily (Igsf) that was originally described in Xenopus and was referred to as cortical thymocyte marker in Xenopus, or CTX. The clone isolated from the human genomic library was called CTH (1). Mature human VSIG2 is a single-pass type I transmembrane protein with a 220 amino acid (aa) extracellular domain (ECD) that contains one C2-type and one V-type immunoglobulin-like domains, and a 63 aa cytoplasmic region linked to the ECD by a short 21 aa transmembrane domain. Human VSIG2 ECD shares 85% and 86% aa sequence identity with mouse and rat VSIG2, respectively. VSIG2 is structurally related to the B7 family of immune regulatory proteins. Our studies at R&D Systems show that VSIG2 inhibits T cell activation, including IL17 and interferon gamma production.

References

  1. Chrétien, I. et al. (1998) Eur. J. Immunol. 28:4094.

Long Name

V-Set and Immunoglobulin Domain Containing 2

Alternate Names

CTH, CTXL

Entrez Gene IDs

23584 (Human); 57276 (Mouse); 300520 (Rat)

Gene Symbol

VSIG2

UniProt

Q96IQ7-1

Additional VSIG2 Products

Product Documents for Recombinant Human VSIG2 Fc Chimera Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human VSIG2 Fc Chimera Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.